Stocktoria
RESMED INC RMD
RESMED INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B | $4.7B | $4.2B | $3.6B | $3.2B | $3.0B | $2.6B | $2.3B | $2.1B | $1.8B |
| Gross profit | $3.1B | $2.7B | $2.4B | $2.0B | $1.8B | $1.7B | $1.5B | $1.3B | $1.2B | $1.1B |
| R&D expense | $331.3M | $307.5M | $287.6M | $253.6M | $225.3M | $201.9M | $180.7M | $155.1M | $144.5M | $118.7M |
| SG&A expense | $991.0M | $917.1M | $874.0M | $737.5M | $670.4M | $676.7M | $645.0M | $600.4M | $554.0M | $488.1M |
| Operating income | $1.7B | $1.3B | $1.1B | $1.0B | $903.7M | $809.7M | $579.3M | $541.8M | $425.8M | $429.0M |
| Interest expense | — | — | — | — | $24.0M | $40.4M | $36.2M | $28.4M | $28.2M | $11.2M |
| Income tax | $276.8M | $243.8M | $204.1M | $181.0M | $409.2M | $111.4M | $114.3M | $205.7M | $76.5M | $87.2M |
| Net income | $1.4B | $1.0B | $897.6M | $779.4M | $474.5M | $621.7M | $404.6M | $315.6M | $342.3M | $352.4M |
| EPS (diluted) | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 | $2.49 |
| Operating cash flow | $1.8B | $1.4B | $693.3M | $351.1M | $736.7M | $802.3M | $459.1M | $505.0M | $414.1M | $547.9M |
| Free cash flow | $1.7B | $1.3B | $573.6M | $216.3M | $634.0M | $706.9M | $390.3M | $442.4M | $351.8M | $489.4M |
| Cash & equivalents | $1.2B | $238.4M | $227.9M | $273.7M | $295.3M | $463.2M | $147.1M | $188.7M | $821.9M | $731.4M |
| Inventory | $927.7M | $822.2M | $998.0M | $743.9M | $457.0M | $416.9M | $349.6M | $268.7M | $268.3M | $224.5M |
| Total assets | $8.2B | $6.9B | $6.8B | $5.1B | $4.7B | $4.6B | $4.1B | $3.1B | $3.5B | $3.3B |
| Total liabilities | $2.2B | $2.0B | $2.6B | $1.7B | $1.8B | $2.1B | $2.0B | $1.0B | $1.5B | $1.6B |
| Shareholders' equity | $6.0B | $4.9B | $4.1B | $3.4B | $2.9B | $2.5B | $2.1B | $2.1B | $2.0B | $1.7B |
Growth · year-over-year · Revenue CAGR 12.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +9.8% | +10.9% | +18.0% | +11.9% | +8.1% | +13.4% | +11.4% | +13.2% | +12.4% | +9.5% |
| Net income growth | +37.2% | +13.7% | +15.2% | +64.3% | -23.7% | +53.7% | +28.2% | -7.8% | -2.9% | -0.1% |
| EPS growth | +37.4% | +13.6% | +14.9% | +63.6% | -24.1% | +52.5% | +27.9% | -8.8% | -3.6% | +0.8% |
| Free cash flow growth | +27.6% | +126.9% | +165.2% | -65.9% | -10.3% | +81.1% | -11.8% | +25.8% | -28.1% | +52.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.